Physician profile
Michael Yordy
NPI 1730159112
$681.68
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $14.40.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $378.81 | 2019-2020 | |
| Coloplast Corp | $68.39 | 2019 | |
| Boston Scientific Corporation | $66.58 | 2019 | |
| Janssen Scientific Affairs, LLC | $34.96 | 2019 | |
| Pfizer INC. | $31.08 | 2019 | |
| Abbvie INC. | $29.85 | 2019 | |
| Janssen Biotech, INC. | $17.22 | 2019 | |
| Endo Pharmaceuticals INC. | $14.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2019 | |
| Allergan, INC. | $13.31 | 2019 | |
| Zyla Life Sciences, INC. | $13.22 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yordy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.